WFRF:(de Herder Wouter W.)
Search: WFRF:(de Herder Wouter W.) > (2020-2023) > Key Device Attribut...
- 8 of 8
- Previous record
- Next record
- To hitlist
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04622naa a2200457 4500 | |
| 001 | oai:lup.lub.lu.se:07327e2e-14bd-4611-a45d-eedc4dbcf80d | |
| 003 | SwePub | |
| 008 | 231201s2023 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://lup.lub.lu.se/record/07327e2e-14bd-4611-a45d-eedc4dbcf80d2 URI |
| 024 | 7 | a https://doi.org/10.1007/s12325-023-02627-62 DOI |
| 040 | a (SwePub)lu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a art2 swepub-publicationtype |
| 072 | 7 | a ref2 swepub-contenttype |
| 100 | 1 | a Jørgensen, Jens Otto Lundeu Aarhus University Hospital4 aut |
| 245 | 1 0 | a Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours |
| 264 | 1 | c 2023 |
| 300 | a 14 s. | |
| 520 | a Introduction: People living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs), administered by either a caregiver or as self-injection via a proprietary or generic device. Injection device attributes that contribute to ease of use and storage, minimise preparation requirements, and reduce injection pain are associated with improved adherence and more favourable therapeutic outcomes. The aim of this study was to assess current opinion surrounding favourable SRL device attributes for people living with acromegaly and NETs as well as that of their caregivers. Methods: Participants (healthcare professionals [HCPs] and patients/non-HCP caregivers) from 11 countries were invited to answer survey questions related to their demographic, experience, and preferences as they relate to the real-world use of injectable SRL devices. Questions were developed based on review of available literature and meetings with a Scientific Committee. Results: Device attributes preferred by the patient/non-HCP caregiver group (n = 211) included confidence that the correct drug amount is delivered (76%), quick administration with minimal pain/discomfort (68%), and device safety (needle-safety and low risk of contamination; 53%). Device attributes preferred by HCPs (n = 52) were quick administration with minimal pain/discomfort (69%), correct use is easy to learn, confidence in handling the device (63%), and confidence that the correct drug amount is delivered (62%). Conclusion: The results identified key features of injection devices for SRL therapy which merit consideration for optimal management and underscore the importance of patient partnership in treatment decisions. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Samhällsfarmaci och klinisk farmaci0 (SwePub)301042 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Social and Clinical Pharmacy0 (SwePub)301042 hsv//eng |
| 653 | a Acromegaly | |
| 653 | a NETs | |
| 653 | a Neuroendocrine tumours | |
| 653 | a Somatostatin receptor ligand | |
| 653 | a SRL | |
| 700 | 1 | a de Herder, Wouter W.u Erasmus University Medical Center4 aut |
| 700 | 1 | a Martin, Wendy A.u King's College Hospital4 aut |
| 700 | 1 | a Kolarova, Teodorau International Neuroendocrine Cancer Alliance - INCA4 aut |
| 700 | 1 | a Marks, Muriëlu World Alliance of Pituitary Organizations (WAPO)4 aut |
| 700 | 1 | a Follin, Ceciliau Lund University,Lunds universitet,Barns och familjers hälsa,Forskargrupper vid Lunds universitet,Medicin/akutsjukvård, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Endokrin,Sena effekter efter barncancerbehandling,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Child and Family Health,Lund University Research Groups,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Endocrine,Late effects after childhood cancer treatment,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)med-cfn |
| 700 | 1 | a Geilvoet, Wandau Erasmus University Medical Center4 aut |
| 700 | 1 | a Melmed, Shlomou Cedars-Sinai Medical Center4 aut |
| 710 | 2 | a Aarhus University Hospitalb Erasmus University Medical Center4 org |
| 773 | 0 | t Advances in Therapyg 40:10, s. 4675-4688q 40:10<4675-4688x 0741-238X |
| 856 | 4 | u http://dx.doi.org/10.1007/s12325-023-02627-6y FULLTEXT |
| 856 | 4 8 | u https://lup.lub.lu.se/record/07327e2e-14bd-4611-a45d-eedc4dbcf80d |
| 856 | 4 8 | u https://doi.org/10.1007/s12325-023-02627-6 |
Find in a library
- Advances in Therapy (Search for host publication in LIBRIS)
To the university's database
- 8 of 8
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Jørgensen, Jens ...
- de Herder, Woute ...
- Martin, Wendy A.
- Kolarova, Teodor ...
- Marks, Muriël
- Follin, Cecilia
- show more...
- Geilvoet, Wanda
- Melmed, Shlomo
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Endocrinology an ...
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Basic Medicine
- and Social and Clini ...
- Articles in the publication
- Advances in Ther ...
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
